IPI Academy

MANAGEMENT forum

Presented by
Management Forum

Regulatory Strategies for Orphan Drugs

14 October 2025

This must-attend event will provide an essential overview of the opportunities and challenges presented by orphan drug regulation.

Format:
Live online

CPD:
6 hours for your records

Certificate of completion

Overview

The market for orphan drug products continues to expand and developing new treatments for rare diseases is becoming an increasingly important growth area for many pharmaceutical companies. This interest in rare and orphan diseases is linked not only to the incentives offered by the different regulatory authorities but also to the recent development of advanced therapies, which are often developed for the treatment of rare diseases.

The interactive course will cover all the key aspects of orphan drug legislation in both the US and EU, including a review of changes proposed in the revised EU orphan drug legislation, and the regulatory processes designed to expidite development and thereby enable earlier access to innovative medicines. The programme will explain in detail the key concepts critical for a thorough understanding of the orphan legislation in the EU and US and how it is applied. The two-stage process of first obtaining the orphan designation and then submitting the MAA/NDA and maintaining the designation as an orphan drug in order to benefit from incentives will be described. We will also cover clinical development considerations and flexibilities that are relevant for orphan drugs.

Case studies will consolidate and illustrate the learning points with real world examples and ensure that you leave the event with practical skills and knowledge that can be put to use in the workplace. The course will allow you not only to learn from our expert trainer but also to share the experiences of other delegates.

Benefits of attending

- **Gain** a detailed overview of the orphan medicinal product legislation in the EU and the US
- **Receive** practical advice on how to prepare and manage orphan submissions
- **Assess** strategic considerations of how orphan status can influence drug development programmes
- **Observe** how the theory is applied to real world examples

Who should attend?

This event will be particularly relevant to regulatory affairs professionals who are involved in orphan drug submissions. It will also be of interest to those working in rare diseases who would benefit from an overview of orphan drug designation.

Programme

Orphan Medicinal Product Legislation

- Overview of the legislation in the EU, US and Japan
  - Including discussion of the ongoing revision to the EU legislation
- What the Regulations cover and why, what they try to protect
- Benefits of Orphan Drug Designation
- Key Considerations
  - Country Submissions
  - Differences of Orphan versus non-orphan
  - Paediatric Conditions

Obtaining Orphan Drug Designation

- Orphan drug designation in the EU
  - Application
  - Procedure
- Similarities and differences with the US
  - Application, procedure and incentives
- Global Issues around Rare Disease
- Strategic Considerations
- Case Study

Maintenance of Orphan Drug Designation

- How to maintain
- Maintenance during MAA and NDA
- Assessment and Case Study

Global Environment

Presenter

Shaun Stapleton

Shaun Stapleton is an independent consultant providing regulatory strategy advice and support to biopharma clients globally.

Shaun held positions of increasing responsibility in regulatory affairs at Sterling Winthrop, Eli Lilly, Boehringer Ingelheim and Ipsen, where he managed regulatory input into development programmes globally, securing new product approvals in the neurology, endocrinology and oncology therapeutic areas.

More recently, Shaun spent 8 years in regulatory consultancy at RRG (a Voisin Consulting Life Sciences Company) where he was a Director and Vice President of Regulatory Science working with global clients on a wide range of regulatory projects. From VCLS he moved to ReNeuron Ltd where he led regulatory, pharmacovigilance and latterly quality aspects of cell therapy and exosome development programmes.

Shaun has extensive experience in orphan drug development from first in man clinical trials through to commercialisation globally. He has been involved in discussions with regulators relating to specific orphan exclusivity issues and chaired the Alliance for Regenerative Medicine working group on “sameness” in the context of market exclusivity for orphan ATMPs (cell therapy). Most recently he was VP and Head of Global Regulatory Affairs at Amryt Pharma, a company specialising in the development and commercialisation of orphan medicines globally, where he contributed to the approval and life cycle management of several orphan drugs in areas of high unmet medical need.

Course date

14 October 2025

Live online
09:00-17:00 **UK (London)** (UTC+01)
Course code 14982

GBP **649** ~~749~~
EUR **909** ~~1,049~~
USD **1,043** ~~1,199~~
Until 09 Sep

How to book

Online:
ipi.academy/2455

Alternatively contact us to book, or if you have any queries:

Email:
info@ipiacademy.com

Phone:
+44 (0)20 7749 4749

Discounts

- Booking more than one delegate on any one date qualifies for a **30% discount** on the second and subsequent places.
- Most events qualify for an **early booking discount** prior to 6 weeks before the course date. Be sure to check on our website, where the latest discounts will be shown.

Further information

Fee
The fee includes all meals and refreshments for the duration of the course (for venue-based courses) and a complete set of course materials (provided electronically). If you have any particular requirements, please advise customer services when booking.

Please note
IPI Academy (and our training partners) reserve the right to change the content and timing of the programme, the speakers, the date and venue due to reasons beyond their control. In the unlikely event that the course is cancelled, we will refund the registration fee and disclaim any further liability.

Terms and conditions
The rest of the our terms, the event cancellation policy and the terms and conditions are on our website, please visit ipi.academy/content/terms-and-conditions

Reviews

★★★★★

Excellent training.

Thiago Loureiro
Sr. manager , Regulatory Strategy
Vertex
Jun 24 2024

★★★★★

Very instructive webinar. Although packed, the day went by quickly.

Ariane Teyssou
Regulatory Affairs Specialist
Enterome
Jun 24 2024

★★★★☆

Well organised and very experienced presenter

Maria Liljevald
Head of Global Regulatory Affairs
Ribocure Pharmaceuticals AB
Jun 24 2024

★★★★★

I believe as a starting point into the world of ODD this was very comprehensive and informative. Very clear and concise.

Khayyam Darr
Senior Regulatory Affairs Executive
Chiesi Ltd
Sep 26 2022

Run this programme in-house for your whole team

Coming to IPI Academy for your in-house training provides an all-inclusive service which gives you access to a wide variety of content, learning platforms and delivery mechanisms as well as your own personal training adviser who will work with you from the initial enquiry through to feedback and follow-up after the programme.

With over 600 trainers, all practitioners and experts across a huge range of fields, we can provide the training you need, where you need it, when you need it, and at a price which suits your budget. Our approach to tailored learning and development consists of designing and delivering the appropriate solution for each client.

For your FREE consultation and to find out more about how we can work with you to solve your training needs, please contact our training advisers:

ALEKSANDRA BEER
Tel: +44 (0)20 7749 4749
Email: inhouse@ipiacademy.com

YESIM NURKO
Tel: +44 (0)20 7749 4749
Email: inhouse@ipiacademy.com

IPI Academy

IPI Academy is a training initiative of Falconbury and Management Forum; leading providers of industry training for over 30 years, based in the UK.

10-12 Rivington Street
London EC2A 3DU

ipi.academy
Tel: +44 (0)20 7749 4749
Email: info@ipiacademy.com